FRI0470 Long-Term (156-Week) Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of 3 Phase III, Randomized, Controlled Trials
2016 ◽
Vol 75
(Suppl 2)
◽
pp. 608.1-608
2015 ◽
Vol 74
(Suppl 2)
◽
pp. 355.3-356
◽
2017 ◽
Vol 76
(6)
◽
pp. AB47
2014 ◽
Vol 73
(Suppl 2)
◽
pp. 742.2-743
◽
2017 ◽
2016 ◽
Vol 75
(Suppl 2)
◽
pp. 346.1-346
2016 ◽
Vol 75
(Suppl 2)
◽
pp. 341.1-341
Keyword(s):
2014 ◽
Vol 73
(Suppl 2)
◽
pp. 90.2-91
◽